Skip to main content
HROW
NASDAQ Life Sciences

Harrow Q3 Revenue $99.3M but Adjusted EBITDA Guidance Cut to $40M+ from $80-100M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$31.143
Mkt Cap
$1.03B
52W Low
$25.76
52W High
$54.85
52W Position info
21% above low
Off High info
43% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

HROW sits 21% above its 52-week low of $25.76 on elevated volume (1.9× avg).

Summary

Harrow posted record Q3 revenue of $99.3 million and $9.8 million of net income, but cut full-year Adjusted EBITDA guidance to more than $40 million from $80-100 million while reaffirming revenue guidance. The IHEEZO QUELL Phase 4 study also missed its primary endpoint.


Key Events · Earnings and Guidance · HROW

  • Record Q3 Revenue of $99.3M

    Revenue rose 39% year over year from $71.6 million, with branded products at $83.5 million, up 62% and about 84% of total. GAAP net income was $9.8 million, including a $5.0 million litigation settlement gain.

  • Adjusted EBITDA Guidance Slashed

    Full-year 2026 Adjusted EBITDA guidance was cut to more than $40 million from $80-100 million, including more than $33 million in Q4. Management cited the first-half VEVYE shortfall, lower gross margins, and accelerated G-MELT, R&D and TYRVAYA spending.

  • Revenue Guidance Reaffirmed, Q4 Bar High

    Full-year revenue guidance held at $350-365 million, requiring Q4 revenue of about $136-151 million — roughly 37-52% sequential growth versus a 2024-2025 average Q3-to-Q4 step-up of about 30%.

  • IHEEZO QUELL Misses Primary Endpoint

    The Phase 4 study did not meet non-inferiority: successful anesthesia in 55.2% of IHEEZO patients versus 59.7% for proparacaine plus subconjunctival lidocaine. Exploratory measures favored IHEEZO on 24-hour pain (2.9 vs 3.7) and adverse events (27% vs 47%).


Analysis · HROW · Life Sciences

The headline is the profit outlook, not the top line. Revenue reached a record $99.3 million, up 39% year over year, and GAAP net income swung to $9.8 million from a $17.3 million loss last quarter. But full-year Adjusted EBITDA guidance was slashed to more than $40 million from $80-100 million, with management citing the first-half VEVYE shortfall, lower gross margins, and pulled-forward spending on the G-MELT NDA, R&D and the TYRVAYA integration. Revenue guidance of $350-365 million was reaffirmed, yet hitting it requires $136-151 million in Q4, roughly 37-52% sequential growth. Separately, the IHEEZO QUELL Phase 4 study missed its primary non-inferiority endpoint, though exploratory pain and tolerability measures favored IHEEZO. The stock now trades against a much lower earnings base than investors were promised.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HROW was trading at $31.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $25.76 to $54.85. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HROW - Latest Insights

HROW
Nov 09, 2026, 5:12 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $31.90
Real-time Price: $31.50 info
Change: -$0.400 (-1%) info
Market Cap: $1.03B info
HROW
Nov 09, 2026, 4:02 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $27.44
Real-time Price: $31.50 info
Change: +$4.06 (+15%) info
Market Cap: $1.03B info
HROW
Oct 05, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.90
Real-time Price: $31.50 info
Change: +$0.600 (+2%) info
Market Cap: $1.03B info
HROW
Aug 21, 2026, 12:09 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $41.61
Real-time Price: $31.50 info
Change: -$10.11 (-24%) info
Market Cap: $1.03B info
HROW
Aug 10, 2026, 4:28 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $40.05
Real-time Price: $31.50 info
Change: -$8.55 (-21%) info
Market Cap: $1.03B info